Fig. 4: Proportion of patients selecting each response option by visit in the FACT-G GP5 item in the atezolizumab-chemotherapy and placebo-chemotherapy arms. | npj Breast Cancer

Fig. 4: Proportion of patients selecting each response option by visit in the FACT-G GP5 item in the atezolizumab-chemotherapy and placebo-chemotherapy arms.

From: Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

Fig. 4

Proportion of patients selecting each response option by a visit in the FACT-G GP5 item (“I am bothered by side effects of treatment”) in a the atezolizumab-chemotherapy arm and b the placebo-chemotherapy arm. BL baseline, C cycle, M month, Tx DC treatment discontinuation.

Back to article page